2023-04
喜讯 | 博生吉医药TAA06注射液顺利完成I期临床试验的首例患者回输
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co. Ltd is a biotech company focusing on developing leading-edge cellular therapeutics. The company is committed to developing CAR-related therapeutic and analytical antibodies, novel CAR- products, and allogeneic cellular therapies. The company has developed a comprehensive pipeline of products and a world-leading allogeneic off-the-shelf UCAR-Vδ1 T-cell R&D platform.
PersonGen.Anke Cellular Therapeutics Co., Ltd.
PersonGen-Anke Cellular Therapeutics Co., Ltd. is a subsidiary company and the manufacturing base of PersonGen BioTherapeutics. The company is equipped with the global-leading fully-automated, closed manufacturing system for cellular therapeutics. It also has the most advanced facilities for the manufacturing of clinical-grade DNA plasmids and lentiviruses. The company has developed fully validated manufacturing processes of CAR-T, allogeneic γδT and UCAR-γδT products.
Read More
PersonGen BioTherapeutics is one of the first company in China focusing on the development of CAR-T and other cellular immunotherapies.
We are driven by our values “Care for People, Cure Every Patient”, and is committed to being the world leader on developing allogeneic cellular therapies against tumors and autoimmunity diseases.
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
2026年4月1日,由谈思生物主办的“CGT Asia 2026 第十届亚洲细胞与基因治疗创新峰会”在上海隆重召开。“CGT行业之星”获奖名...
近日,国际生物医药领域权威媒体PharmaBoardroom重磅刊发博生吉医药创始人、董事长兼CEO杨林博士的独家专访,稿件同步通过平台官方...
从“个体化定制”到“通用型现货”,再到如今备受瞩目的“体内生成”,细胞治疗的技术演进正以前所未有的速度重塑着创新药的未来格局。当行业仍在为如...
BIOCHINA2026于2026年3月12日在苏州国际博览中心盛大开幕!作为本次盛会的核心内容板块,此次BIOCHINA2026 围绕“高...
Conceptual Pilot Study, Patient Recruitment
Read More